2425P Low androgen expression in tumors and benefit from docetaxel – validation of the APUC 6 genes as a prognostic and predictive biomarker in CHAARTED prostate cancer trial
Xuezhong Shi, Jinseub Hwang, P. Sutera, Krishnan R. Patel(National Institutes of Health), Charles J. Ryan(University of Minnesota), Chad Tang(The University of Texas MD Anderson Cancer Center), P.T. Tran, J. Wang, C. Sweeney, Ravi A. Madan(National Cancer Institute), Ella Boytim(University of Minnesota), J.A. Proudfoot, E.S. Antonarakis, Amol C. Shetty(University of Maryland, Baltimore), M. Deek, Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Phi Duong Nguyễn, E. Davicioni, Arif Hussain(Baltimore VA Medical Center), Yue Song(Zhengzhou University)
Cited by 0
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k